EU patent for IML-106 granted
It is a great pleasure to have received the message from the EU Patent Office in Munich, that the in July 2015 filed patent for IML-106 has been approved after long scrutiny by the EU Patent Office this March. The patent extents to the substance IML-106 for the treatment HIV infections and AIDS.
The patent termin is valid until July 2035. More information and the whole patent text can be requested from us.
Image source: © Elionas2 – pixabay.com
Comments are closed.